US Patent

US12453755 — GIP/GLP1 agonist compositions

Method of Use · Assigned to Eli Lilly and Co · Expires 2039-06-14 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a composition of the drug tirzepatide, specifically a formulation that includes sodium chloride, propylene glycol, and dibasic sodium phosphate.

USPTO Abstract

A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4377 — Mounjaro
U-4376 — Mounjaro
U-4386 — Mounjaro
U-4375 — Mounjaro
U-4383 — Mounjaro
U-4378 — Mounjaro
U-4380 — Mounjaro
U-4380 — Mounjaro
U-4376 — Mounjaro
U-4384 — Mounjaro
U-4381 — Mounjaro
U-4379 — Mounjaro

Patent Metadata

Patent number
US12453755
Jurisdiction
US
Classification
Method of Use
Expires
2039-06-14
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.